Literature DB >> 2988109

The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.

B Wallmark, P Lorentzon, H Larsson.   

Abstract

In order to study the mechanism of inhibition of gastric acid secretion by omeprazole, its action was investigated in several different in vitro preparations. In preparations from isolated gastric mucosa, isolated rabbit gastric glands and isolated parietal cells, omeprazole was found to inhibit both basal and stimulated acid secretion. These effects were seen irrespective of whether acid formation was stimulated by histamine or by db-cAMP. The inhibitory pattern of omeprazole was found to be of a non-competitive nature against db-cAMP stimulation. Furthermore, in isolated glands, omeprazole was found to inhibit stimulation induced by high medium K+ and low Na+ concentrations. The basal membrane of the intact gland preparation was made permeable to molecules of large size by the use of digitonin, and acid secretion was subsequently initiated by the addition of exogenous ATP. Even under these conditions, omeprazole was found to be inhibitory, with an IC50-value comparable to that of intact glands. SCN- was found to mimic the action of omeprazole in that it counteracted both basal and stimulated acid secretion in the test models described above. In contrast, cimetidine was found to inhibit only histamine stimulation, consonant with its H2-receptor-blocking properties. In the gastric gland preparation, changes in oxygen consumption is closely related to changes in acid formation. When oxygen consumption and acid formation were measured in parallel under histamine stimulation, another benzimidazole, timoprazole (H 83/69) (structurally related to omeprazole), was found to inhibit both parameters. However, under non-stimulated conditions, timoprazole was found to have only a minor effect on the oxygen consumption. The isolated H+K+ATPase preparation was used in order to investigate the effects of omeprazole at the "proton pump level". This enzyme was found to be inhibited by omeprazole in a pH-dependent manner. Under neutral or slightly alkaline conditions, slight inhibition occurred. When the pH of the incubation media was progressively decreased, the inhibitory activity of omeprazole was augmented. Several reactions of the H+K+ATPase enzyme cycle were investigated, i.e., K+-stimulated ATPase- and pNPPase- activities and formation of phosphoenzyme. All three of these reactions were inhibited. The results presented are in agreement with the hypothesis that omeprazole inhibits gastric acid secretion by blocking the gastric H+K+ATPase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988109

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  22 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Authors:  T Andersson; C Cederberg; C G Regårdh; I Skånberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Influence of acid secretory status on absorption of omeprazole from enteric coated granules.

Authors:  T Andersson; R Bergstrand; C Cederberg
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.

Authors:  T Tateishi; S G Graham; Y Krivoruk; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

7.  Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

Authors:  T Andersson; K Andrén; C Cederberg; P O Lagerström; P Lundborg; I Skånberg
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 8.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

9.  Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.

Authors:  T Lind; C Cederberg; M Olausson; L Olbe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  A study of the interaction between omeprazole and cyclosporine in renal transplant patients.

Authors:  I Blohmé; J P Idström; T Andersson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.